Supplementary Table 1. Percentage of participants who exhibited specific patterns of remission and relapse.

Diagnosis	*N*	Never seized, before or during study	No history of seizures, but seizures started during study, and then:					History of seizures before study, not seizing at study start (1st remission), and then:						History of seizures before study, continued seizing at study start, and then:					
			had 1st remission	had 1st relapse	had 2nd remission	had 2nd relapse	never experienced remission	remained in remission throughout the study	had 1st relapse	had 2nd remission	had 2nd relapse	had 3rd remission	had 3rd relapse	had 1st remission	had 1st relapse	had 2nd remission	had 2nd relapse	had 3rd remission	never experienced remission
Classic Rett syndrome female	915	30.8%	3.6%	1.1%	0.9%		9.2%	16.5%	3.9%	3.4%	1.2%	1.0%	0.1%	4.7%	3.6%	1.6%	0.7%	0.1%	17.6%
Atypical mild Rett syndrome female	78	44.9%	1.3%	1.3%		1.3%	3.8%	25.6%	1.3%	6.4%				2.6%	3.8%	1.3%	1.3%		5.1%
Atypical severe Rett syndrome female	81	22.2%	6.2%			1.2%	6.2%	22.2%	3.7%	1.2%		2.5%		4.9%	7.4%	2.5%			19.8%
MECP2 mutation female without clinical Rett syndrome	42	69.0%	2.4%	2.4%				16.7%							2.4%				7.1%
MECP2 duplication female	8	87.5%						12.5%											
CDKL5	2													50.0%					50.0%
Classic Rett syndrome male	1		100.0%																
Atypical severe Rett syndrome male	1																		100.0%
MECP2 mutation male without clinical Rett syndrome	20	40.0%					5.0%	15.0%	5.0%	5.0%					10.0%				20.0%
MECP2 duplication male	28	50.0%					7.1%	14.3%	3.6%						7.1%				17.9%
Not all participants had complete historical data, therefore n is less than total n in study.																			

CDKL5 = cyclin-dependent kinase-like 5; *MECP2* = Methyl-CpG Binding Protein 2 gene